Transfusion transmission of HCV, a long but successful road map to safety

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1423-1429

  Selvarajah, Suganya ^a,b   Busch, Michael P ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

BLOOD DONOR; BLOOD SAFETY; DEMOGRAPHY; GENOTYPE; HEALTH CARE PRACTICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MASS SCREENING; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SAFETY; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION;

BLOOD BANKS; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; DEVELOPING COUNTRIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE; RNA, VIRAL; UNITED STATES; VIREMIA;

EID: 84871986837     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2459     Document Type: Review

References (38)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362. (Pubitemid 19117877)
2. Grady GF, Chalmers TC. Risk of post-transfusion viral hepatitis. N Engl J Med 1964; 271:337-342.
3. Tobler LH, Busch MP. History of posttransfusion hepatitis. Clin Chem 1997; 43:1487-1493. (Pubitemid 27329806)
4. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 1970; 211:261-265.
5. Gocke DJ, Greenberg HB, Kavey NB. Hepatitis antigen. Detection of infectious blood donors. Lancet 1969; 2:248-249.
6. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77:691-699.
7. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494-1500. (Pubitemid 20015539)
8. Couroucé AM, Le Marrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second-and third-generation anti-HCV assays. Transfusion 1994; 34:790-795. (Pubitemid 24304629)
9. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351:760-768.
10. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45:994-1002. (Pubitemid 40798792)
11. Roth WK, Busch MP, Schuller A, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102:82-90.
12. Selvarajah S, Tobler LH, Simmons G, Busch MP. Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol 2010; 17:550-557.
13. Shata MT, Tricoche N, Perkus M, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003; 314:601-616. (Pubitemid 37209981)
14. Katayama K, Kumagai J, Komiya Y, et al. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004; 47:57-64. (Pubitemid 38420868)
15. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49:2454-2489.
16. Busch MP, Murthy KK, Kleinman SH, et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012; 119:6326-6334.
17. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495-1504.
18. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012; 26:119-128
19. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756-762. (Pubitemid 30118647)
20. Busch MP, Glynn SA, Stramer SL, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006; 46:469-475.
21. Delwart E, Slikas E, Stramer SL, et al. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 2012; 205:875-885.
22. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200:1216-1226.
23. Katz LM. How can the blood transfusion medicine community contribute to public health in tough economic times? J Infect Dis 2012; 205:867-869.
24. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1:74-81.
25. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-115.
26. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2:61-80.
27. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 Suppl 2:30-60.
28. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31 Suppl 2:18-29.
29. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 Suppl 2:1-3.
30. Scheiblauer H, El-Nageh M, Nick S, Fields H, Prince A, Diaz S. Evaluation of the performance of 44 assays used in countries with limited resources for the detection of antibodies to hepatitis C virus. Transfusion 2006; 46:708-718.
31. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8:200-206. (Pubitemid 32672971)
32. Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26 Suppl 3:29S-33S. (Pubitemid 27388068)
33. Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008; 15:120-128.
34. Shimizu YK, Weiner AJ, Rosenblatt J, et al. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A 1990; 87:6441-6444.
35. Operskalski EA, Mosley JW, Tobler LH, et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003; 43:1433-1441. (Pubitemid 37322505)
36. Mosley JW, Operskalski EA, Tobler LH, et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005; 42:86-92. (Pubitemid 40911315)
37. Selvarajah S, Keating S, Heitman J, et al. Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent HCV infection. J Gen Virol 2012; 93:1673-1679.
38. Busch MP, Glynn SA. Use of blood-donor and transfusion-recipient biospecimen repositories to address emerging blood-safety concerns and advance infectious disease research: the National Heart, Lung, and Blood Institute Biologic Specimen Repository. J Infect Dis 2009; 199:1564-1566.